Accès libre

Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes

Anze Smole

Anze Smole

Immunology and Cellular Immunotherapy (ICI) Group, Department of Genetic Toxicology and Cancer Biology, National Institute of BiologyLjubljana, Slovenia
Recherchez cet auteur sur
Sciendo|Google Scholar
Smole, Anze
  
13 déc. 2022
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes's Cover Image
À propos de cet article
Article précédent
Article suivant
Citez
Télécharger la couverture
Catégorie d'article: review
Publié en ligne: 13 déc. 2022
Pages: 409 - 419
Reçu: 19 oct. 2022
Accepté: 27 oct. 2022
DOI: https://doi.org/10.2478/raon-2022-0049
Mots clés
© 2022 Anze Smole, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

Figure 1

The principle of adoptive cellular immunotherapy. CAR = chimeric antigen receptor; TCR = T-cell receptor
The principle of adoptive cellular immunotherapy. CAR = chimeric antigen receptor; TCR = T-cell receptor

Figure 2

Schematics of the basic CAR architecture. CAR = chimeric antigen receptor; scFv = single-chain variable fragment
Schematics of the basic CAR architecture. CAR = chimeric antigen receptor; scFv = single-chain variable fragment

Figure 3

Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.
Challenges of cellular immunotherapy with chimeric antigen receptor (CAR) T cells.
Langue:
Anglais
Périodicité:
4 fois par an
Sujets de la revue:
Médecine, Médecine clinique, Médecine interne, Hématologie, oncologie, Radiologie
RSS Feed de la revue